Analyst Price Targets — ITGR
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 23, 2026 2:40 pm | — | Raymond James | $101.00 | $84.95 | TheFly | Integer price target raised to $101 from $95 at Raymond James |
| December 18, 2025 2:11 pm | Richard Newitter | Truist Financial | $95.00 | $80.60 | TheFly | Integer price target raised to $95 from $86 at Truist |
| November 24, 2025 1:41 pm | — | Truist Financial | $86.00 | $69.61 | TheFly | Integer price target lowered to $86 from $88 at Truist |
| October 24, 2025 1:19 pm | — | Truist Financial | $88.00 | $73.89 | TheFly | Integer price target lowered to $88 from $121 at Truist |
| October 24, 2025 12:35 pm | Matt O'Brien | Piper Sandler | $82.00 | $73.89 | StreetInsider | Integer Holding (ITGR) PT Lowered at Piper Sandler as 'Soft 2026 Sales Outlook Steals Investor Focus' |
| October 24, 2025 12:27 pm | — | Raymond James | $95.00 | $73.89 | TheFly | Integer price target lowered to $95 from $143 at Raymond James |
| October 21, 2025 10:42 am | Brett Fishbin | KeyBanc | $133.00 | $107.37 | TheFly | Integer price target lowered to $133 from $145 at KeyBanc |
| October 15, 2025 12:36 pm | — | Truist Financial | $121.00 | $104.27 | TheFly | Integer price target lowered to $121 from $137 at Truist |
| April 25, 2025 3:58 pm | Richard Newitter | Truist Financial | $150.00 | $121.49 | TheFly | Integer price target raised to $150 from $140 at Truist |
| December 11, 2024 1:07 pm | Richard Newitter | Truist Financial | $163.00 | $140.62 | TheFly | Integer price target raised to $163 from $147 at Truist |
Latest News for ITGR
PLANO, Texas, April 06, 2026 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE: ITGR), a leading global medical device contract development and manufacturing organization (CDMO), today announced Pamela G. Bailey, who currently serves as Integer's independent Chair of the Board, will not stand for re-election at the Company's 2026 Annual Meeting of Stockholders, scheduled for May 20, 2026.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Integer (NYSE: ITGR - Get Free Report) and NeuroPace (NASDAQ: NPCE - Get Free Report) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, institutional ownership, valuation, profitability, analyst recommendations, earnings and dividends. Insider and Institutional Ownership 99.3% of Integer shares are held
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
PLANO, Texas, April 02, 2026 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE: ITGR), a leading global medical device contract development and manufacturing organization (CDMO), announced today that it will webcast its conference call to discuss financial results and business highlights for the first quarter ended April 3, 2026, on Thursday, April 30, 2026, at 8 a.m. CT (9 a.m.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for ITGR.
U.S. House Trading
No House trades found for ITGR.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.